Thailand PGT CMS

博客

  • Repeated Blastocyst Culture Failure or Few Usable Embryos After PGT: What to Review Before Treatment in Thailand

    When several cycles have ended before blastocyst stage, or PGT has left only one or two embryos that could be considered for transfer, the next attempt is rarely helped by simply booking another cycle. What tends to change the conversation is a clear, dated record of what the laboratory actually observed and what the genetic report actually said. That record is what a treating clinician in Thailand — or anywhere — needs in order to review your history rather than start from scratch.

    This guide is about preparation, not prediction. It explains which documents to collect, how to summarise culture and PGT outcomes in a way a clinic can use, and which questions belong with a licensed clinician rather than with a coordinator. Decisions about testing, embryo selection and whether another cycle is appropriate are clinical and individual; no article can tell you your chances.

    Start with the two separate questions hiding in your history

    “Repeated failure” can describe two different problems, and they are reviewed differently:

    • Development before testing. Embryos that slow down, arrest, or never form a blastocyst. The relevant evidence sits in the embryology laboratory’s day-by-day records.
    • Results after testing. Blastocysts formed and were biopsied, but few or none were reported as suitable for transfer after PGT. The relevant evidence sits in the genetic testing report.

    Many patients have some of both. Keeping them separate in your own summary helps a clinician see where the bottleneck may lie — and prevents a PGT report from being read as an explanation for problems that happened before any biopsy.

    Build a dated record set before you contact any clinic

    Clinics can only review what they can read. Ask each previous clinic for copies of the following, and note the date and source of every document. If a report is missing, record that it is missing rather than reconstructing it from memory.

    • Cycle summaries for each attempt: start date, protocol name, and the outcome recorded by the clinic.
    • Stimulation and medication details: which medications, doses, monitoring results and trigger timing, as recorded in your file.
    • Embryology or laboratory reports: fertilisation method, day-by-day embryo development, blastocyst formation, biopsy and vitrification details (see the next section).
    • PGT reports with embryo-level classifications, not just a total count.
    • Prior uterine and medical workup: any imaging, procedures, blood tests or other investigations already completed, with dates.
    • Transfer history, if any embryos were transferred, including how each transfer was managed.

    If you are earlier in the process and simply have few embryos, the preparation steps in Few Usable Embryos: What to Prepare and Ask Before IVF in Thailand overlap closely with this list.

    How to summarise culture outcomes so a laboratory can follow them

    An embryology report is most useful when it is specific. Where your records allow, summarise each cycle in a short table or list covering:

    • Fertilisation method used (for example, conventional insemination or ICSI) and the number of eggs retrieved, mature, and fertilised.
    • Cleavage and blastocyst development: how many embryos were still developing on each recorded day.
    • Arrest timing: the day on which embryos stopped developing, if the laboratory recorded it.
    • Blastocyst formation rate for that cycle, as stated in the report.
    • Biopsy and vitrification details: how many blastocysts were biopsied, how many were frozen, and on which day.

    If the laboratory used a grading system, include the grades exactly as written rather than translating them. Different clinics use different schemes, and a clinician will interpret them in context. What matters is that the original wording survives the transfer between clinics.

    How to summarise PGT results without flattening them

    A single line such as “two normal embryos” loses most of the information a clinician needs. The test type matters, because PGT-A, PGT-M and PGT-SR answer different questions: PGT-A assesses chromosome number, PGT-M concerns a known single-gene condition, and PGT-SR concerns chromosomal structural rearrangements, as the HFEA’s patient information on PGT-M and PGT-SR explains. If you are unsure which test you had, that is itself a question for the reporting laboratory.

    For each testing round, record:

    • the test type performed and the reporting laboratory;
    • the number of embryos biopsied;
    • the counts reported as euploid, aneuploid, mosaic or inconclusive, per embryo where the report gives that detail;
    • any comments or limitations the laboratory included.

    Two points are worth holding in mind. First, PGT-A is a test with limitations and can produce incorrect findings; a result does not guarantee a successful pregnancy or a healthy child, as the HFEA’s PGT-A information notes. Second, a mosaic result is inferred from intermediate findings in a small biopsy sample, and technical factors can contribute to such findings; the sample does not establish the cell composition of the whole embryo, according to the ASRM committee opinion on mosaic PGT-A results. That is why the original report, with its wording, is more useful than a summary.

    If the accuracy and limits of chromosome screening are part of what you want to understand, Understanding PGT-A Accuracy in Thailand covers that ground in more depth.

    What to put in front of a treating clinician

    Once the records are assembled, the review conversation can focus on your actual history. These are clinical questions, and they belong with a licensed clinician who can see your reports — not with a coordination service, which does not diagnose or prescribe.

    • What do my culture records suggest about where development is being lost, and does that change how a next cycle would be planned?
    • Were there laboratory factors in my previous cycles that are worth understanding — for example, how embryos were cultured, selected for biopsy, or frozen?
    • Given my PGT report, how should the reported categories be interpreted for my case, including any mosaic or inconclusive results?
    • Is further testing — of embryos, of me, or of a partner — likely to change a decision, or would it add information without changing the plan?
    • Would a different approach be reasonable to discuss, and what would it be intended to address?
    • What are the uncertainties, and what would you want to review again before deciding?

    It is reasonable to ask about individual chances and risks directly. A clinician can discuss them for your situation; what no one can offer is a guarantee of embryos, pregnancy or a healthy child.

    Turning the review into a practical plan

    Records work is the slowest part of preparing for treatment abroad, so start it early. A coordination service can help organise the documents, prepare a dated checklist with outstanding items clearly marked, and communicate document requests and questions to a hospital. Clinicians interpret the results; sharing records requires your agreement on who receives them and how.

    If you want a remote review before travelling, appointment and remote-consultation coordination can request a format, a records list and confirmation of availability and any fees — all subject to the hospital’s confirmation. Travel and language arrangements are best planned around confirmed appointments rather than assumed schedules. And before you return home, decide which records you will ask for and who should receive them, so follow-up questions can be answered without starting over.

    If you are comparing how clinics present their laboratory and testing arrangements, it helps to read shortlists as research starting points rather than as evidence of better outcomes. A countrywide overview of IVF hospitals and clinics in Thailand can orient that comparison; the clinical review of your own records remains the deciding step.

  • Poor Fertilization or Embryo Quality: What to Check Before IVF in Thailand

    A low fertilization rate or a cycle that ended with few usable embryos is frustrating partly because the explanation is often buried in details that never reach the patient. Before you book flights or choose a clinic in Thailand, the most valuable step is usually not another test but a careful reconstruction of what actually happened in the previous cycle — and a conversation with a treating clinician about what those records can and cannot tell them.

    This guide covers what to request from your previous clinic, how to read those documents well enough to ask sensible questions, and how to sequence the review so that travel decisions come after clinical ones rather than before.

    Start with the laboratory report, not the summary

    Patients often arrive at a consultation with a single sentence: “poor fertilization” or “bad embryo quality.” That phrase hides the numbers a clinician needs. Ask the previous clinic for the full embryology record, including:

    • Fertilization method used — conventional IVF, ICSI, or a split approach — and whether it was planned in advance or changed on the day.
    • Egg numbers — how many eggs were retrieved, and how many were mature. Fertilization rate is usually calculated against mature eggs, so a report without this denominator is hard to interpret.
    • Fertilization results — how many eggs fertilized normally, and whether any showed abnormal fertilization patterns.
    • Embryo development — day-by-day numbers, day-3 and day-5/6 grades, and any notes on fragmentation, cleavage timing or arrest.
    • What happened to each embryo — transferred, frozen, biopsied or discarded, and why.

    If the clinic only issues a discharge summary, ask specifically for the embryology laboratory report. It is a different document and it is the one that carries the detail.

    Request the semen analysis in full

    Male-factor findings are a common thread in poor fertilization histories, and the details matter. Ask for the original semen analysis report rather than a verbal summary, including concentration, motility, morphology, volume and any comments the embryologist added on the day of the cycle. If sperm DNA fragmentation testing or a more detailed morphology assessment was done, request those reports too.

    Two cautions are worth knowing before you build a plan around these results. First, sperm DNA fragmentation test methods and their interpretation are not standardised, so a single number should be discussed with a clinician rather than treated as a verdict. Second, add-on sperm-selection techniques marketed after such testing — including magnetic sorting (MACS) and high-magnification selection (IMSI) — have been assessed by the UK fertility regulator as lacking sufficient moderate- or high-quality evidence that they improve the chance of having a baby, including in male-factor infertility. That does not make them forbidden topics; it means a clinic should be able to explain its own reasoning rather than present them as an obvious upgrade. You can read more about planning around sperm findings in IVF for male factor infertility in Thailand.

    Separate the three possible bottlenecks

    “Poor embryo quality” is a description, not a diagnosis. When you review the records, try to place the problem in one of three broad areas, because each leads to different questions:

    Where the cycle faltered What the records should show What to raise with the clinician
    Egg numbers or maturity Retrieved versus mature eggs; stimulation record Whether the previous protocol suited you, and what a clinician would consider changing
    Fertilization Method used; normal versus abnormal fertilization counts Whether the fertilization approach was appropriate and why
    Embryo development Daily cleavage, grading, fragmentation notes, arrest pattern How the lab assesses embryos and what the pattern suggests

    Many cycles show problems in more than one area, and sometimes no clear cause is found. A clinician may also conclude that the previous cycle was simply a low-yield cycle without an identifiable fault. That is a legitimate outcome of a review, and it is better to hear it before travelling than to assume a change of country will change the result.

    Ask how the Thai laboratory fertilizes and grades

    Fertilization method and embryo assessment are clinical decisions made by the treating team, not by a coordination service. What you can reasonably ask before committing is how those decisions are made at the clinic you are considering:

    • Under what circumstances does the team choose conventional IVF, and when does it recommend ICSI? What would prompt that choice in your case?
    • Who performs embryo grading, against what criteria, and will you receive the laboratory report rather than only a summary?
    • Can the laboratory review your previous records in advance, and does that review happen before or during your visit?
    • If embryo quality is again poor, what would the team want to discuss with you at that point?

    If preimplantation genetic testing is part of your history or your questions, keep the distinction clear: PGT-A assesses chromosome number in cells sampled from an embryo, and it has limitations — it can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child. A biopsy also carries a risk of damage that can prevent further development. PGT-M and PGT-SR address different questions again, relating to a known monogenic condition or a chromosomal structural rearrangement. None of these tests repairs embryo quality; they describe or select among embryos that already exist. For background on how laboratories are assessed, see PGT IVF lab quality in Thailand.

    Sequence the work before the travel

    The timing question is really a sequencing question. A practical order looks like this:

    1. Collect records from the previous clinic — embryology report, stimulation record, semen analysis, operative and transfer notes.
    2. Organise them into a dated file with a short cover note listing what is included and what is still outstanding.
    3. Request a remote consultation with the clinic you are considering, sending the records ahead so the clinician can review them before the appointment.
    4. Hold travel bookings until the clinic has confirmed the appointment format, what it can review remotely, and what would need to happen in person.
    5. Plan the return-home handover — which records you will ask for, who should receive them, and which follow-up questions remain open.

    This is where a coordination service can help without crossing into clinical territory: assembling the record set, sending document requests to the hospital, arranging the remote appointment, and later requesting records for your own doctor at home. Clinicians interpret the results and make the treatment decisions; coordination does not diagnose, prescribe or promise a particular outcome. If you want to understand what a case review involves, you can request a Thailand IVF case review.

    A worked example of the record set

    Suppose a couple had one cycle abroad that yielded nine eggs, five mature, two fertilized by conventional IVF, and one day-5 blastocyst of moderate grade that did not implant. A useful file for a Thai consultation would contain: the stimulation chart with drug names and doses; the retrieval note confirming nine eggs and five mature; the embryology report showing the fertilization method and the two fertilized eggs; the day-by-day development notes explaining why three embryos arrested; the embryology grading sheet for the blastocyst; a full semen analysis from around that time; and the transfer note. With that file, a clinician can discuss whether the fertilization method was the limiting step, whether maturity was the issue, or whether the picture is unexplained. Without it, the conversation stays at the level of “poor fertilization” and nobody learns much.

    What a review cannot promise

    Prior records inform a consultation; they do not guarantee a different outcome. Fertilization and embryo development vary between cycles, and a change of clinic or country is not itself a treatment. Some patients learn that the previous cycle was unremarkable in hindsight; others learn that a specific, addressable factor was missed. Both are useful, and both are better known before you commit to travel dates. If a cycle has already failed and you are deciding what comes next, preparing for a failed IVF cycle covers the emotional and practical side of that decision.

    One practical reminder: keep your own dated copy of every record you send, and do not change any medication while you wait for a consultation — that instruction belongs to your treating clinician.

    Frequently asked questions

    Can a Thai clinic tell from my old records why fertilization was low?

    Sometimes. A full embryology report showing egg maturity, fertilization method and daily embryo development gives a clinician real material to work with. In other cases the records are incomplete or the cycle shows no clear cause, and the review itself becomes the honest answer. Either way, the review is a clinical judgement made by the treating team, not something a coordination service can determine in advance.

    Should I repeat tests before travelling or wait until the consultation?

    That depends on what your records already show and what the clinic asks for. Sending the existing reports first usually avoids duplicating tests that were recently done, but a clinician may still want updated results. Ask the clinic which tests, if any, they want completed before a remote appointment so that you are not arranging them twice.

  • Reviewing Prior IVF Cycles Before Travel to Thailand for Repeated Implantation Failure

    Repeated implantation failure is a description of a pattern, not a diagnosis you can settle from your own records. Before you book flights to Thailand, the most useful preparation is usually not more searching for clinics. It is a clear, cycle-by-cycle account of what has already happened, written in a form a treating clinician can read quickly and question directly.

    This guide sets out how to build that account, how to keep the language precise, and how to sequence the practical steps so that travel follows a clinical plan rather than the other way round. Deciding what further evaluation you need, and whether any additional testing is appropriate, belongs to licensed clinicians who can review your history. A coordinator can help you organise records and communicate with a hospital, but does not diagnose or prescribe.

    Start by naming the pattern accurately

    “Repeated implantation failure” and “recurrent non-implantation” are often used loosely. In practice, clinicians may apply different definitions, and the definition matters because it changes which cycles count and which questions are worth asking.

    Two distinctions are worth getting right before you write anything down:

    • Implantation failure versus pregnancy loss. A cycle where a pregnancy was confirmed and then lost is a different clinical event from a cycle where no pregnancy was ever detected. Mixing them in one summary can obscure the pattern.
    • Transferred versus not transferred. A cycle that never reached embryo transfer — because no embryo was available, transfer was cancelled, or the cycle was frozen for later — is not evidence about implantation. Keep those cycles in your records but label them clearly.

    Ask the clinic you approach which definition it uses and how it would classify your history. That is a reasonable clinical question, and the answer helps you understand what the consultation is actually assessing. If you want a broader look at how records are organised for this situation, see IVF after recurrent implantation failure: records to organise first.

    Build one row per cycle, not one paragraph per clinic

    A narrative summary is hard to compare across cycles. A table with the same fields for every cycle is easier for a clinician to scan and easier for you to spot gaps. You do not need every field for every cycle; mark unknown items as “not recorded” rather than guessing.

    Field What to record Why it matters
    Dates Approximate start of stimulation, trigger date, transfer date Gives the sequence and interval between cycles
    Stimulation and trigger Protocol name if known, trigger type, any cancelled or converted cycle Shows how the cycle was managed, not just its outcome
    Eggs and embryos Number of eggs collected, number fertilised, number reaching blastocyst Describes the embryo cohort available in that cycle
    Embryo details Stage at transfer, grading as reported, fresh or frozen, number transferred Transfer-stage and grading language varies between clinics; copy the original wording
    Genetic testing Whether any embryo was tested, which test, and the reported result Testing status changes how a cycle should be interpreted
    Endometrial preparation Thickness and pattern as reported, medication approach Part of the transfer environment record
    Transfer notes Catheter used, any difficulty noted, technique comments Occasionally relevant; keep the clinic’s own wording
    Luteal support Type and duration as prescribed Completes the cycle record
    Outcome Pregnancy test result, any confirmed pregnancy, any loss Separates implantation from loss
    Other findings Uterine assessment results, sperm findings, any comments from the treating team Connects the cycle to investigations already done

    Copy clinic wording rather than translating it into your own terms. If a report says “expanded blastocyst, grade 4BB”, write that, not “good embryo”. If a report gives a mosaic result, note the reported finding as a sample-level result rather than a settled description of the whole embryo; the ASRM committee opinion explains that a mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample, that technical factors can contribute, and that a sampled result does not establish the cell composition of the whole embryo. Those points are worth raising with the treating clinician and genetic counsellor rather than resolving yourself.

    Collect the documents behind the table

    The table is a summary; the consultation will need the source documents. A practical records pack usually includes:

    • Discharge or cycle summaries for each attempt, with dates
    • Embryology reports, including grading and any testing reports
    • Operative or procedure notes for transfers and any uterine assessment
    • Medication lists for stimulation and luteal support
    • Laboratory results relevant to the cycles, including any sperm analysis reports
    • Any imaging or pathology reports already performed

    Keep a one-page index at the front listing what is included and what is missing. That index is often more useful than a long covering letter, because it tells the clinician where the gaps are. If a report is only available in another language, ask the hospital in advance whether a translation is needed and who should provide it.

    Decide what to ask before you decide where to go

    Once the summary exists, the questions become more specific. Useful areas to raise with a treating clinician include:

    • How the clinic defines repeated implantation failure, and how it would classify your cycles
    • Whether any further evaluation is indicated, and what it would involve
    • Whether any embryo testing is relevant to your history, and what its limitations are
    • What the clinic would want to review before suggesting a plan
    • What can reasonably be arranged remotely and what requires being in Thailand

    On testing specifically, it helps to understand the boundaries. PGT-A assesses chromosome number in cells sampled from an embryo, and the HFEA notes that testing has limitations and can produce incorrect findings; whether to use it should be discussed for the individual situation, and a result does not guarantee a successful pregnancy or a healthy child. Embryo biopsy can also cause damage and prevent further development. These are reasons to ask how a test would change your plan, not reasons to rule anything out on your own. For a closer look at the debate, see PGT-A for repeated implantation failure in Thailand: does it help?

    A pre-travel sequence that keeps decisions in order

    The temptation after repeated disappointment is to book travel first and sort out the clinical questions later. A different order usually produces a calmer trip.

    1. Compile the cycle table and records pack. Mark unknown fields honestly.
    2. Write your question list. Group it into definition, evaluation, testing and logistics.
    3. Request a remote consultation. Ask what format is available, what records the clinician wants in advance, and whether a fee applies.
    4. Confirm outstanding documents. Note which reports you still need to request from earlier clinics, and how long that may take.
    5. Wait for the clinical plan. Only then compare quotations and confirm what each includes.
    6. Book travel around confirmed appointments. Keep appointment location, language assistance and any companion’s needs in the same plan.

    If you are still at the stage of comparing providers, the countrywide IVF clinics and hospitals in Thailand for international patients directory is a neutral starting point for research; it is a navigation aid, not a statement that any provider is clinically better for your history.

    Where coordination helps, and where it stops

    A coordination service can organise the records pack, draft the outstanding-document list, request appointments and remote consultations, and help with language and travel-stage arrangements around confirmed appointments. It can also help request records and pass follow-up questions back to the hospital after you return home.

    It does not interpret your results, decide whether further evaluation is needed, recommend a protocol, or predict your chance of pregnancy. Those are clinical judgements for the treating team. Keeping that line clear is not a limitation on your questions — you should ask clinicians about diagnosis, options, risks, reports and your individual chances as directly as you wish.

    One practical note: if you are currently taking medication as part of a cycle or preparation, do not change it because of something you read while planning travel. Ask the prescribing clinician. Recording approximate dates and keeping your own copy of every report is useful; altering treatment is not a planning decision.

    A worked example of the summary format

    Suppose a patient has had three transfers. Cycle one was a fresh transfer of one blastocyst, no pregnancy. Cycle two was a frozen transfer of two blastocysts after a uterine assessment, no pregnancy. Cycle three was a frozen transfer that was cancelled before transfer because of fluid in the cavity. A good summary would show three rows, but would label cycle three as “no transfer” so it is not counted as an implantation failure. The question list would then ask how the clinic classifies the history, whether the cancelled cycle changes anything, and what the uterine assessment found. That is a far more productive starting point than a paragraph saying “three failed IVFs”.

    If you want to think through the next attempt more broadly, planning your next IVF cycle in Thailand after a previous failure covers the planning side, and how to prepare for a failed IVF cycle in Thailand may help if a cycle has just ended. When you are ready to ask for help assembling records or requesting a consultation, you can request a Thailand IVF case review.

  • Day-Five, Day-Six and Day-Seven Blastocyst Labels: What the Numbers Mean

    If your embryo report lists something like “day-5 blastocyst” or “day-6 blastocyst,” the number is a timing note. It records the day, counted from insemination or fertilisation, on which the laboratory observed that embryo reach the blastocyst stage. It is not the day of your transfer, it is not a grade, and it is not a genetic test result.

    That single sentence answers most of the confusion. The rest of this guide explains why the timing differs between embryos, how to read the label next to the other information in your report, and what is worth confirming with the treating team.

    What the laboratory is actually recording

    After fertilisation, an embryo divides through several stages. At the blastocyst stage it has formed a fluid-filled cavity and two distinguishable cell populations: the inner cell mass, which will form the fetus, and the trophectoderm, which will form the placenta. Embryos do not all arrive at this point on the same day.

    In a typical reporting convention, day 0 is the day of insemination or fertilisation. An embryo first seen as a blastocyst on the fifth day after that is labelled day 5; one that gets there on the sixth or seventh day is labelled day 6 or day 7. The label therefore describes developmental pace in the laboratory’s culture, observed on a particular day.

    Two practical points follow. First, laboratories differ in how they count days and when they inspect embryos, so the same embryo could in principle be described slightly differently elsewhere. Second, the label is a snapshot of one observation, not a running commentary on everything that happened in the incubator.

    Why some embryos reach the blastocyst stage later

    Development is a biological process with natural variation. Some embryos simply take longer to form a cavity and organise their cells. The day label captures that difference in pace; it does not, by itself, explain the cause.

    This matters because patients often read a later day number as a verdict. It is better understood as one piece of laboratory information among several. How much weight a clinic gives to developmental timing, and how it combines that with morphology grading, is a matter of that clinic’s own criteria and experience. Those criteria are not universal, and they are not something a general guide can supply for your specific embryo.

    Reading the label alongside the rest of the report

    A day label rarely appears alone. Most reports also include a morphology grade describing the expansion of the cavity, the inner cell mass and the trophectoderm, and, where testing was performed, a separate genetic result. These are different kinds of information and should not be collapsed into one another.

    Item on the report What it describes What it does not describe
    Day number (5, 6 or 7) When the blastocyst stage was first observed, counted from insemination or fertilisation Quality, genetic status, or the day of transfer
    Morphology grade Appearance of the cavity, inner cell mass and trophectoderm at assessment A guarantee of implantation or a genetic result
    PGT report (if performed) Findings from cells sampled from the embryo A whole-embryo diagnosis or a guarantee of a healthy child

    Keeping these rows separate in your mind is useful when you speak to the clinic, because each one answers a different question. If you are still working out how a genetic result is worded, the guide to reading PGT-A results after IVF walks through the common categories, and PGT-A result categories explained in plain language covers what to ask a clinician to clarify.

    It also helps to know what PGT-A can and cannot do. The HFEA describes PGT-A as assessing chromosome number in cells sampled from an embryo, and notes that testing has limitations and can produce incorrect findings; a result does not guarantee a successful pregnancy or a healthy child. A day label sits outside that discussion entirely — it is a timing observation, not a test.

    What the day label does not mean

    • It is not a quality score. A day-6 blastocyst is not automatically “worse” than a day-5 one, and a day-5 label does not certify a strong embryo.
    • It is not a transfer date. Transfer timing is a separate clinical and logistical decision.
    • It is not a genetic result. PGT findings come from a separate report and a separate laboratory process.
    • It is not a prediction of your individual chance of pregnancy. That depends on many factors your clinician can discuss with you.
    • It is not comparable across clinics without checking. Counting conventions and assessment schedules vary between laboratories.

    Day-7 blastocysts in particular

    Day-7 blastocysts are a recognised but less common category. Because they are less common, clinics differ in whether they continue culturing to day 7 at all, and in their policies on transferring or freezing embryos that reach the blastocyst stage that late. Some laboratories may not routinely culture beyond day 6. This is a service and policy question for the clinic, not something a general article can settle.

    If your report includes a day-7 embryo, the useful next step is to ask the treating team how they view it in your specific situation, including whether it would be considered for transfer, freezing or further testing, and on what basis.

    Questions worth putting to the treating team

    These are clinical and laboratory questions, and the embryology or medical team is the right source for the answers. You can ask them directly, in a consultation or by message through the clinic’s usual channel.

    1. How does this laboratory count days — from insemination, from fertilisation, or from another reference point?
    2. When are embryos assessed, and could an embryo’s label change if it were assessed on a different schedule?
    3. Does the laboratory routinely culture embryos to day 7, and what is its policy on day-7 embryos?
    4. How does the clinic weigh developmental timing against morphology grade when selecting among embryos?
    5. How should I read this day label together with the morphology grade and any PGT report?
    6. What would you want me to understand about this particular embryo’s report?

    If you are also trying to understand the wider sequence — what happens between retrieval and the report landing in your inbox — the overview of what happens between egg retrieval and the embryo report sets out the stages, and how long PGT-A biopsy takes and whether it adds time to a cycle covers the laboratory timeline. For the difference between earlier-stage embryos and blastocysts, see cleavage-stage embryos and blastocysts compared.

    Keeping your own record straight

    Reports arrive at stressful moments, and small details blur. A simple habit helps: note the date you received each report, keep the original document unedited, and write down the day label, morphology grade and any PGT wording exactly as printed rather than paraphrasing from memory. If you are comparing information from more than one clinic, keep each clinic’s documents separate so conventions are not mixed up.

    If you are preparing questions before a consultation, it can help to sort them into three groups: what the report says, what it means for your options, and what happens next. The first group is often answerable from the documents themselves; the second and third belong with the treating clinician.

    Where coordination help fits, and where it does not

    Arranging a remote consultation, gathering records before an appointment, or requesting a copy of a laboratory report after you return home are practical tasks that a coordination service can assist with. Interpreting what a day label means for your embryo, recommending whether to transfer or freeze a particular embryo, and advising on your individual chances are clinical matters for the treating team and, where relevant, a genetic counsellor.

    If you would like help organising your questions and the documents you already hold before approaching a hospital, you can request a case review. The output is a structured question list and a record checklist with unconfirmed items clearly marked — not a medical opinion.

    Frequently asked questions

    Does a day-5 blastocyst have a better chance than a day-6 blastocyst?

    The day number records when the blastocyst stage was first observed, not a quality rating. How much weight a clinic gives to developmental timing, alongside morphology grading and any other information, is a matter of that clinic's own criteria. Your treating clinician is the right person to discuss what the label means for your specific embryo.

    If my embryo is labelled day 6, does that mean it developed too slowly?

    It means the laboratory first observed the blastocyst stage on the sixth day after insemination or fertilisation, which reflects natural variation in developmental pace in culture. Whether that timing matters for your situation depends on the clinic's criteria and the rest of the embryo's report, so it is worth asking the embryology or medical team directly.

  • Why Egg Retrieval and Embryo Transfer May Happen in Separate Cycles

    Egg retrieval and embryo transfer are two stages of the same IVF pathway, but they do not have to happen in the same menstrual cycle. In a split or “freeze-all” approach, embryos are created and frozen after retrieval, and a transfer is planned for a later cycle. This is a deliberate scheduling decision, not a sign that something went wrong.

    The short answer: separating the two stages gives the treating team room to let your ovaries and hormone environment settle, to prepare the lining of the uterus on its own timeline, to wait for test results if embryos are being screened, and to reduce the chance that a fresh transfer coincides with a risk of ovarian hyperstimulation. Which of these reasons applies to you is a clinical judgement, and the balance differs from person to person.

    What “separate cycles” actually means

    In a fresh transfer, an embryo is placed in the uterus a few days after retrieval, while the body is still responding to the stimulation cycle. In a separate-cycle plan, all suitable embryos are frozen, and the transfer happens in a later cycle after the uterus has been prepared, often with medication and monitoring.

    Both are recognised ways to organise IVF. Neither is automatically better. The right structure depends on how the stimulation cycle went, how many embryos are available, whether testing is planned, your age and history, and what your clinician considers safest and most sensible for you.

    Reasons the two stages are often split

    Letting the ovaries and hormone environment recover

    Ovarian stimulation deliberately pushes hormone levels well above a normal cycle. Some clinicians prefer to let that settle before preparing the uterus, so the transfer cycle starts from a calmer baseline. This is a matter of clinical timing rather than a fixed rule, and the interval your team recommends may vary.

    Preparing the uterine lining on its own schedule

    When transfer is planned separately, the lining can be built and monitored without the hormonal noise of a stimulation cycle running alongside it. For some patients this makes the timing of transfer more controllable, particularly when travel has to be booked in advance. Ask your clinician whether they plan a medicated, natural or modified cycle, because the monitoring schedule and your dates will differ.

    Waiting for embryo testing results

    If preimplantation genetic testing (PGT) is part of the plan, cells are sampled from embryos and analysed, and the results are not available within the few days a fresh transfer would require. A separate cycle allows the transfer to be planned once results are reported and discussed. PGT-A looks at chromosome number in sampled cells; PGT-M concerns a known single-gene condition; PGT-SR concerns a known chromosomal structural rearrangement. Each addresses a different question, and testing has limitations — it cannot guarantee a pregnancy or a healthy child, and results can occasionally be incorrect or need careful interpretation.

    If a PGT-A result is reported as mosaic, that describes intermediate chromosome findings in the sampled cells. It does not establish the cell composition of the whole embryo, and technical factors can contribute to such findings. Those results, and the uncertainty around them, are best discussed with your treating clinician and a genetic counsellor before any transfer decision.

    Reducing the chance of a fresh transfer during ovarian hyperstimulation

    Ovarian hyperstimulation syndrome (OHSS) is a recognised risk of stimulation, and a fresh transfer in a cycle where that risk is elevated may be avoided. Freezing embryos and transferring later is one way clinicians manage this. Whether your cycle carries that concern is something only your treating team can assess from your monitoring.

    Practical scheduling and travel

    For international patients, a gap between retrieval and transfer can also make the trip more workable. Retrieval and recovery happen in one visit, and the transfer can be planned for a later date once results and the lining are confirmed. That said, a separate cycle usually means two trips or a longer stay, so it is worth comparing the practical cost and time implications before assuming it is simpler.

    How the decision is usually made

    The choice is normally made around the time of retrieval, once the team can see how many eggs were collected, how embryos are developing, and whether testing is planned. Your clinician should be able to explain the reasoning in your own case — this is the “doctor explanation” that matters more than any general rule.

    Useful things to clarify with your treating clinician:

    • Why a separate cycle is being recommended for you, and which of the reasons above applies.
    • Whether a fresh transfer was considered and why it was set aside.
    • What type of transfer cycle is planned and what monitoring it involves.
    • How long the interval is expected to be, and what has to happen before transfer can be scheduled.
    • Whether any results need to be reported and discussed before a transfer date is set.
    • What would change the plan — for example, if no embryo is suitable for testing or transfer.

    These are clinical questions, and they belong with your doctor and, where relevant, a genetic counsellor. A coordination service can help you organise the questions and pass them on, but it does not diagnose, interpret results or recommend a treatment plan.

    Planning the gap as an international patient

    Once the structure is clear, the practical work is mostly about dates, records and communication. A few things help:

    • Ask for the expected interval in writing, with the caveat that it may change after results or monitoring.
    • Keep a dated record of retrieval, embryo freezing, any testing, and the start of the transfer cycle preparation.
    • Confirm who communicates results and by what method, and who your agreed contact is.
    • Check what happens between trips — which monitoring can be done locally, and what the clinic needs to see.
    • Plan the return-home handoff: which records you will need, and how follow-up questions will be handled after you leave.

    If you are comparing hospitals, it helps to ask how each one structures separate-cycle transfers, what is included in a quoted package, and what would be charged separately. A hospital price list is easier to read when you know which items are staged across two cycles. For a broader view of how the stages fit together, see the IVF process timeline for international patients and the step-by-step PGT IVF overview.

    A worked planning example

    Suppose a patient travels for retrieval and is told that embryos will be frozen and tested, with transfer planned for a later visit. The practical questions become: when will results be reported, who will explain them, how long the transfer cycle preparation takes, and whether monitoring can start at home. Writing these down before the appointment, and asking for the expected dates in writing, turns a vague gap into a plan the patient can book travel around — while accepting that the dates may shift.

    Where this fits with PGT-specific timing

    This article explains the general reasons retrieval and transfer may be separated. The narrower question of how a fresh versus frozen transfer is planned specifically after PGT is covered separately in fresh versus frozen embryo transfer planning and in the guide to frozen embryo transfer preparation and medication questions. If cost is part of your decision, the Thailand IVF budget planning guide and the article on staged payments and transfers can help you see how a two-stage plan affects what you pay and when.

    The bottom line

    Separate cycles are a common and intentional way to organise IVF. The reasons usually combine recovery time, lining preparation, waiting for test results, managing OHSS risk and practical scheduling. The right structure for you is a clinical decision, and the most useful thing you can do is ask your treating team to explain their reasoning for your case, then plan dates, records and communication around that explanation.

    Frequently asked questions

    Does a separate cycle mean the first cycle failed?

    No. Splitting retrieval and transfer is a planned structure, not a failure. It is chosen for reasons such as letting the ovaries settle, preparing the lining separately, waiting for embryo testing results, or reducing the chance of transferring during a cycle with elevated OHSS risk. Your clinician can explain which reason applies to you.

    How long is the gap between retrieval and transfer usually?

    There is no single interval that applies to everyone. It depends on your recovery, the type of transfer cycle planned, whether results are pending, and your clinic's protocol. Ask your treating team for the expected interval in writing, and treat it as an estimate that may change after results or monitoring.

  • Fresh vs Frozen Embryo Transfer: What Actually Differs

    A fresh embryo transfer and a frozen embryo transfer can both place an embryo in the uterus. The defining difference is timing: in a fresh transfer, the embryo is transferred during the same cycle in which the eggs were retrieved and fertilised. In a frozen transfer, the embryo is vitrified (rapidly frozen), stored, and transferred in a later cycle.

    That single difference shapes almost everything else — how the recipient’s cycle is prepared, how many visits are involved, how long you wait, and how a trip to Thailand fits around treatment. Neither pathway is universally better. Which one a clinician may discuss with you depends on your individual situation, and that judgement belongs with your treating team.

    The core difference in plain terms

    In a fresh cycle, stimulation, egg retrieval, fertilisation and transfer are compressed into one treatment cycle. The embryo develops in the laboratory for a few days and is then transferred, without being frozen.

    In a frozen cycle, the embryo is created and frozen first. The transfer happens later, after the embryo has been warmed and the recipient’s uterus has been prepared. The two events — making the embryo and transferring it — are separated in time.

    This is why the two pathways are sometimes described as different treatment stages rather than different treatments. The embryo creation step is similar; what changes is when and how the transfer step is arranged.

    Why a freeze-all approach may be discussed

    Clinicians sometimes recommend freezing all suitable embryos and planning a later transfer. This is a clinical decision, not a default, and the reasons vary. Common themes a treating team may raise include:

    • Genetic testing is planned. When embryos are sent for preimplantation genetic testing, results are not available within the fresh-transfer window. Freezing allows the transfer to wait for the report. Our guide to fresh versus frozen transfer after PGT explains how testing changes the timeline.
    • The uterine lining or hormone profile after stimulation is not ideal. Ovarian stimulation produces high hormone levels that can affect the lining. A clinician may judge that a later, separately prepared cycle gives a better chance of a receptive uterus.
    • Symptoms or risk of ovarian hyperstimulation syndrome (OHSS). If a cycle produces many follicles or early signs of OHSS, a clinician may prefer to avoid a fresh transfer and let the body settle first.
    • Practical or medical reasons to pause. Sometimes the decision is about giving the patient time — for recovery, for other health matters, or for planning.

    These are reasons a clinician may discuss, not recommendations you should apply to yourself. The right approach depends on your history, your response to stimulation and your test results.

    How the recipient’s cycle is prepared differently

    In a fresh transfer, the recipient’s own cycle — driven by the stimulation medications — is the transfer cycle. There is no separate preparation phase for the uterus beyond what the stimulation cycle already involves.

    In a frozen transfer, the uterus needs to be prepared to receive the embryo. Two broad approaches are often described:

    • A natural or modified natural cycle. The body’s own ovulation is tracked, and the transfer is timed around it. This may involve monitoring visits to detect ovulation.
    • A hormone-prepared (medicated) cycle. Hormone medication is used to build the lining, and the transfer is scheduled around that. This gives the clinic more control over timing, which can matter for travel planning.

    In both approaches, the clinic monitors the lining — usually by ultrasound — before scheduling the transfer. The specific protocol, medication and monitoring schedule are clinical decisions made by your treating team.

    What the patient experiences differently

    The practical experience differs in ways that matter for international patients planning a trip.

    Practical point Fresh transfer Frozen transfer
    Number of treatment phases One combined cycle Two phases: embryo creation, then a later transfer cycle
    Waiting interval Transfer a few days after retrieval A gap between freezing and transfer; length depends on the plan and your cycle
    Monitoring visits Focused on the stimulation cycle Additional visits to prepare and monitor the lining
    Travel implications One concentrated trip may cover retrieval and transfer May allow a first trip for retrieval and a second for transfer, or a longer stay
    Timing flexibility Limited; the transfer follows the stimulation cycle Often more flexible, especially with a hormone-prepared cycle

    For someone travelling to Thailand, the frozen pathway can sometimes be split across two trips, with the transfer scheduled once the embryo is stored and the lining plan is set. The fresh pathway usually keeps everything in one window. Neither is automatically easier — it depends on your work, family and travel constraints. Our preparation timeline for international patients sets out the planning steps around transfer.

    Questions worth putting to your treating clinician

    Because suitability is an individual clinical judgement, the most useful preparation is a focused conversation with your treating team. You might ask:

    • Based on my history and this cycle’s response, which pathway would you discuss with me, and why?
    • If testing is planned, how does that affect the timing of a transfer?
    • What signs or results would make you lean towards freezing all embryos?
    • For a frozen transfer, which preparation approach would you consider for me, and what monitoring would it involve?
    • How many visits would each pathway require, and can any be done remotely or locally?
    • What are the known limitations or risks of each pathway in my situation?

    These are clinical questions, and your clinician is the right person to answer them. A coordinator can help you organise the questions and the records, but cannot diagnose, prescribe or advise on which pathway is medically suitable for you.

    Records and reports to have ready for a remote consultation

    A remote consultation about fresh versus frozen transfer is more useful when the clinician has the right documents. Consider gathering:

    • Previous stimulation cycle details, including medication doses and response.
    • Any history of OHSS or a high follicle count.
    • Ultrasound reports describing the lining and ovaries.
    • Hormone blood test results from previous cycles.
    • Any genetic testing reports, if PGT has been done or is planned.
    • A written list of your questions and priorities.

    If you are comparing quotations from more than one clinic, check what each includes — for example, whether a frozen transfer quote covers storage, warming, monitoring visits and medication. Our article on whether frozen transfer is cheaper than fresh explains why headline prices can be misleading.

    Planning the two pathways as separate stages

    One helpful way to think about the choice is to treat embryo creation and embryo transfer as two stages that can be planned separately. Our guide to planning separate treatment stages walks through how that works in practice, including what to confirm before booking travel.

    If you would like help organising your records, preparing questions for a remote consultation, or coordinating appointment requests with a hospital in Thailand, you can request a case review. Coordination support does not replace clinical advice, and no appointment or outcome can be guaranteed.

    Neither pathway is universally superior

    Fresh and frozen transfer are both established approaches. Some patients transfer fresh embryos; others freeze and transfer later. The choice depends on your clinical picture, your response to stimulation, whether testing is involved, and your practical circumstances.

    It is reasonable to ask your clinician to explain the reasoning behind a recommendation, and to ask what would change their view. What matters is that the decision is made with your treating team, using your own results — not from a general comparison alone.

  • Why a Euploid PGT-A Result Does Not Guarantee Implantation

    A euploid PGT-A result is reassuring, and it is easy to read it as a promise. It is not one. The result describes the chromosome number seen in a small sample of cells taken from the embryo. It does not confirm that every cell in that embryo is normal, and it says nothing about whether the embryo will continue developing, hatch from its shell, or meet a uterus ready to receive it.

    That is why a euploid result can sit alongside a transfer that does not lead to pregnancy. The gap has two parts: what the test can and cannot see, and everything outside the test that still has to go right. Keeping those two layers separate makes a report easier to interpret and makes a conversation with your clinician more useful.

    What a euploid result actually describes

    PGT-A assesses chromosome number in cells sampled from an embryo. In typical practice the sample comes from the trophectoderm, the outer layer that will form the placenta, not from the inner cell mass that will form the fetus. The lab reports what it found in that sample.

    So a euploid call is best understood as a probability statement about the sampled cells. It means the sample showed the expected number of chromosomes. It is not a whole-embryo diagnosis and not a statement about the future pregnancy. The UK regulator’s patient information makes the same point plainly: testing has limitations, can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child (HFEA: PGT-A).

    This is also why the test is a discussion point rather than an automatic step. Whether PGT-A suits a particular situation depends on history, age, the number of embryos available and what you want the information for. Your treating team can weigh those factors with you.

    Test limits: where a euploid report stops short

    Several limits sit between “the sample looked euploid” and “this embryo is chromosomally normal in every cell.” None of them means the test is useless. They mean the result needs context.

    The sample is not the whole embryo

    A biopsy removes a few cells from one region of the embryo. The rest of the embryo is not tested. A normal-looking sample makes an abnormal whole embryo less likely, but it cannot rule it out. This sampling gap is the core reason a euploid result is probabilistic rather than definitive.

    Mosaicism complicates the picture

    Sometimes a report shows intermediate chromosome copy-number findings rather than a clean euploid or aneuploid call. This is described as mosaicism, and it is inferred from the biopsy sample. Technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo. The ASRM committee opinion on mosaic PGT-A results recommends that these findings and their uncertainty be discussed with the treating clinician and a genetic counsellor (ASRM: mosaic PGT-A results). If your report uses mosaic language, that is a conversation to have with your clinician, not a label to interpret alone.

    No-result and inconclusive calls happen

    Not every biopsy yields a clear answer. A sample can fail to amplify, give an unclear signal, or be reported as inconclusive. An inconclusive result is not the same as an abnormal one, and it is not the same as a normal one. Ask what the specific wording on your report means for that embryo and what options exist.

    Platform resolution has boundaries

    Different testing approaches look at chromosomes at different levels of detail. A test designed to count chromosomes may not detect very small changes, and it is not a test for single-gene conditions. PGT-M addresses a known monogenic condition, and PGT-SR addresses chromosomal structural rearrangements; these are different questions from the one PGT-A asks (HFEA: PGT-M and PGT-SR). Knowing which test you had matters when you read the report.

    The biopsy itself carries a small risk

    Embryo biopsy can cause damage and prevent further development. The HFEA notes this as a recognised risk of the procedure (HFEA PGT-A FAQ). It is one more reason the decision to test is individual rather than universal.

    Other factors: what has to go right after the report

    Even setting test limits aside, implantation is not a single event that a chromosome result can control. A euploid embryo still has to complete several biological steps, and the recipient’s body has to be ready at the same time.

    • Embryo developmental potential. An embryo can arrest or fail to hatch after transfer. A chromosome result does not measure these capacities.
    • Endometrial receptivity. The lining has to be receptive at the right moment. Timing and uterine factors sit outside the embryo report.
    • Transfer technique and cycle management. How and when the transfer is performed is part of the clinical picture.
    • Maternal age and general health. These shape the wider context in which a transfer takes place.
    • Clinical history. Previous cycles, diagnoses and prior outcomes inform how your clinician interprets this attempt.

    These factors are why two embryos with the same euploid report can have different outcomes, and why a single failed transfer does not mean the report was wrong. Your clinician can explain which factors are most relevant in your case.

    Per-embryo versus per-transfer: two different questions

    Reports and conversations often blur two questions. The first is about one embryo: does this sample look euploid? The second is about one transfer: will this transfer lead to implantation and an ongoing pregnancy? The first is an input to the second, not the answer to it.

    When you read a report, notice which question it is answering. A euploid call answers the first. It cannot answer the second on its own, because the second depends on the embryo’s full development, the uterine environment and the clinical plan. If someone presents a euploid result as a guarantee, that framing is worth questioning.

    Reading your own report in context

    A useful way to approach a PGT-A report is to separate what the laboratory states from what your clinician interprets.

    What the lab typically reports What it does not establish
    The chromosome finding for the sampled cells The chromosome status of every cell in the embryo
    Whether the call is euploid, aneuploid, mosaic or inconclusive Whether the embryo will implant or develop into a healthy child
    The test performed and its stated scope Single-gene conditions or structural rearrangements unless a different test was used

    For a closer walk through report wording, see how to interpret PGT-A results from a Thai lab and the companion guide on reading a PGT-A report from a Thai laboratory. If your report includes mosaic language, what mosaic PGT-A results mean explains the terminology. For the underlying test purpose, what PGT-A is and why it is used in IVF gives the broader background.

    What to ask your clinician about your individual chances

    You are entitled to ask your treating clinician about your own situation, including what a euploid result does and does not change for you. Questions that tend to produce a useful conversation include:

    • Which test was performed on this embryo, and what does the report’s wording mean in plain language?
    • Does this report include any mosaic or inconclusive findings, and how should those be interpreted?
    • Given my age, history and this cycle, how do you frame the chance of implantation for this transfer?
    • Which factors outside the embryo report are most relevant in my case?
    • If this transfer does not lead to pregnancy, what would you want to review before the next step?

    These are clinical questions, and they belong with your treating team. A coordination service can help you organise records and prepare questions, but it does not diagnose, interpret results for you or prescribe. The clinician who knows your history is the right person to discuss individual chances.

    Practical preparation for an international patient

    If you are travelling to Thailand for treatment, the report conversation is easier when your records are in order before you arrive. A dated list of prior cycles, test reports and current medications helps your clinician see the full picture. If you are comparing clinics, ask how each one handles report discussions and who will explain results to you; a shortlist of providers is a starting point for those questions, not evidence that one clinic will give you a better outcome.

    Remote consultations can be used to go through report wording before travel, and to clarify what will be explained in person. After you return home, a written summary of what was discussed and any outstanding questions is worth requesting so that follow-up does not depend on memory. Coordination can assist with organising records, requesting appointments and passing questions to the hospital; clinical interpretation and medical decisions remain with your treating team.

    The takeaway

    A euploid PGT-A result is genuinely useful information, and it is not a guarantee. It reflects the sampled cells, carries the limits of sampling, mosaicism, inconclusive calls and platform resolution, and it cannot control embryo development, endometrial receptivity, transfer factors or your wider health context. Read the report as one input, ask your clinician what it means for you specifically, and treat any promise of guaranteed implantation with caution.

    Frequently asked questions

    If my embryo is euploid, why did the transfer still fail?

    A euploid result describes the sampled cells, not the whole embryo or the pregnancy. Implantation also depends on embryo development, endometrial receptivity, transfer factors and your clinical history. A failed transfer does not mean the report was wrong; your clinician can review what happened in your case.

    Does a euploid result mean my baby will be healthy?

    No. PGT-A assesses chromosome number in a sample of embryo cells, and the HFEA states that a result does not guarantee a successful pregnancy or a healthy child. Your clinician can explain what the test does and does not cover for your situation.

  • Cleavage-Stage Embryos and Blastocysts: How the Two Stages Differ

    Cleavage-stage embryo and blastocyst are not two kinds of embryo. They are two points on the same developmental path. An embryo that reaches the blastocyst stage has passed through the cleavage stage first. The practical differences are about timing, what the laboratory can see, and what can be done with the embryo at each point.

    This guide explains the sequence, what is observable at each stage, and how those differences shape conversations about PGT and transfer. It does not tell you which stage is right for your treatment; that depends on your own cycle and your treating team’s assessment.

    The short answer

    A cleavage-stage embryo is typically observed around day 2 to day 3 after fertilisation. It has divided into a small number of cells, called blastomeres, and each of those cells can usually be seen individually. There is no fluid-filled cavity.

    A blastocyst is typically observed around day 5 to day 6. The cells have compacted, a fluid-filled cavity has formed, and two distinct populations of cells have appeared: the inner cell mass, which is associated with the future fetus, and the trophectoderm, the outer layer associated with the placenta. These descriptions are general embryology; the exact day an individual embryo reaches a stage varies.

    A day-by-day view of early development

    The timeline below describes the usual sequence after fertilisation. It is a general pattern, not a schedule your embryos must follow.

    • Day 0 to day 1: fertilisation occurs, and the resulting single-cell zygote begins dividing.
    • Day 2 to day 3: the embryo is in the cleavage stage, with a small number of visible cells and no cavity.
    • Day 3 to day 4: the cells begin to compact and adhere more tightly, a transition sometimes called morula formation.
    • Day 5 to day 6: a cavity forms and the embryo becomes a blastocyst, with an inner cell mass and trophectoderm.

    Some embryos develop more slowly or stop developing altogether. A laboratory report that says an embryo had not reached blastocyst by a given day is a description of that embryo at that moment, not a prediction about any future cycle.

    Side-by-side comparison

    Feature Cleavage stage Blastocyst stage
    Typical timing Around day 2 to day 3 after fertilisation Around day 5 to day 6 after fertilisation
    Visible structure Individual cells (blastomeres), no cavity Compacted cells, fluid-filled cavity, inner cell mass and trophectoderm
    Typical reporting language Cell number, symmetry, degree of fragmentation Expansion or hatching description, inner cell mass and trophectoderm grading
    What the laboratory can assess Cell count and appearance of the visible cells Overall structure and the appearance of the two cell populations
    What the laboratory cannot assess Chromosome number or genetic content from appearance alone; how the embryo would have developed later Chromosome number or genetic content from appearance alone; whether an embryo would implant

    Grading systems differ between laboratories, and the same embryo can be described in different words by different teams. If you are comparing reports, it helps to ask each laboratory to explain its own scale rather than assuming the numbers mean the same thing. A separate guide on comparing embryo grading explanations between IVF laboratories sets out what to check.

    Why PGT biopsy is generally done at the blastocyst stage

    PGT-A assesses chromosome number in cells sampled from an embryo. The sample is a biopsy, and the result describes the sampled cells, not the whole embryo with certainty. Testing has limitations and can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child.

    At the blastocyst stage, the trophectoderm is a separate outer layer, so a biopsy can be taken from those cells while the inner cell mass remains. At the cleavage stage, every visible cell is still part of the same undifferentiated group, so removing a cell is a different proposition. This is why trophectoderm biopsy at blastocyst stage is the usual approach in PGT programmes.

    Biopsy is not risk-free. Embryo biopsy can cause damage and prevent further development. How that risk applies in your situation is a question for your treating clinician and embryologist, not something a general article can quantify for you.

    What happens if embryos do not reach blastocyst

    Extended culture to blastocyst means waiting longer before transfer or freezing. Some embryos stop developing during that wait. If none of your embryos reach the blastocyst stage, there may be no trophectoderm sample to test and no blastocyst to transfer or freeze from that cycle. That outcome is a reason for a careful conversation with your clinician about what the laboratory observed and what options exist, not a verdict on future attempts.

    Because extended culture can reduce the number of embryos available for transfer or freezing, clinics sometimes discuss transferring at cleavage stage instead. That trade-off is a clinical decision for your team, based on your history and the laboratory’s observations.

    Vitrification and transfer timing

    Embryos can be vitrified (fast-cooled) at either stage, and the stage at which an embryo is frozen is recorded in the laboratory report. Transfer timing follows from that: a cleavage-stage transfer happens earlier in the cycle than a blastocyst transfer, and a frozen transfer is scheduled separately from the retrieval cycle.

    Whether a fresh or frozen transfer is planned after PGT is a separate decision with its own considerations. A comparison of fresh versus frozen embryo transfer after PGT covers the pathway differences without recommending one for you.

    Questions worth putting to your own embryologist or clinician

    These are clinical questions, and your treating team is the right place to ask them. A short written list helps you get specific answers rather than general ones.

    • At which stage does this laboratory usually report embryos, and what does its grading scale mean?
    • If extended culture is planned, on which day is blastocyst development assessed, and what happens to embryos that have not reached blastocyst by then?
    • If PGT is planned, which cells are sampled, and what does the report describe?
    • If few or no embryos reach blastocyst in a cycle, what will the team review with us afterwards?
    • At which stage would any embryo be frozen, and how does that affect transfer scheduling?

    You can also ask for the laboratory’s written embryo report and for an explanation of any term you do not recognise. Reports are clinical documents; interpretation belongs with your clinician.

    Where coordination help fits

    Understanding the stages is the clinical part. The practical part is making sure questions reach the right person and that records travel with you. A coordination service can help organise your existing records and a dated list of outstanding documents, request an appointment or remote consultation and confirm the format and any fee status, and assist with language and travel planning around confirmed appointments. After you return home, it can help request records and route follow-up questions to the hospital. It does not interpret results, diagnose, prescribe or promise an outcome, and appointment availability always depends on the hospital.

    If you are at the stage of comparing what clinics include in their written quotations, the guide to what to confirm in writing about PGT-A testing cost in Thailand lists the items worth checking. For a broader look at how clinic success-rate claims are presented, see how to read clinic success-rate claims.

    Sources: Embryo biopsy can cause damage and prevent further development. — HFEA PGT-A frequently asked questions (checked 2026-10-15).

    Frequently asked questions

    Does a blastocyst-stage embryo have a better chance than a cleavage-stage embryo?

    That is a clinical question about your own cycle, and the answer depends on the embryos, your history and the laboratory. What can be said generally is that reaching blastocyst is a sign that an embryo has continued developing, but it does not guarantee implantation or a healthy pregnancy. Ask your treating clinician how the stage question applies to your situation.

    Can PGT be done on a cleavage-stage embryo?

    Trophectoderm biopsy at blastocyst stage is the usual approach because the outer cell layer can be sampled separately from the inner cell mass. Whether any alternative is appropriate in your case is a decision for your treating team and the laboratory, and it should be discussed with you directly rather than assumed.

  • MACS and Sperm DNA Fragmentation: What the Evidence Shows and Where It Stops

    If you have read about sperm DNA fragmentation and then come across magnetic-activated cell sorting (MACS), the natural question is whether one fixes the other. The short answer is that MACS can change some laboratory measurements, but the evidence that it improves the chance of having a baby is not established. That gap between a measurable effect and a proven benefit is the heart of this topic.

    This guide explains what MACS is meant to do, how the research is built, and why regulators and guideline bodies have not treated it as routine. It also sets out what you can usefully clarify with the treating clinician, since only they can advise on an individual case.

    What MACS is designed to do

    MACS uses magnetic sorting to separate sperm according to surface signals associated with damaged or dying cells, as described by the HFEA’s page on sperm DNA fragmentation and sperm selection. In the version most often discussed, a marker called annexin-V binds to phosphatidylserine that has moved to the outer surface of a sperm membrane — a change associated with cell stress or early death. Magnetic particles attached to that marker let a laboratory deplete the labelled sperm and keep the unlabelled fraction.

    The logic is appealing: if you can remove sperm with damaged membranes, the remaining sample might carry less DNA damage. The important word is might. A laboratory can show that a marker was removed. That is not the same as showing that a pregnancy is more likely.

    How the evidence is structured

    Research on MACS is not one large, consistent body of work. It is better pictured as several layers, each answering a different question.

    • Laboratory studies measure things such as DNA fragmentation index (DFI), motility and morphology after sorting. These are surrogate endpoints: they describe the sample, not the patient’s outcome.
    • Small clinical trials often come from a single centre and compare MACS with standard preparation in selected groups, such as couples with high DFI or repeated implantation failure. Sample sizes are frequently small, which makes chance findings harder to rule out.
    • Meta-analyses pool those studies. Pooling helps with numbers but cannot fix underlying differences in MACS protocols, DFI assay methods or which patients were included.
    • Clinical endpoints — fertilisation, implantation, clinical pregnancy, live birth and miscarriage — are the outcomes that matter most to patients, and they are the least consistently reported.

    The HFEA’s assessment is that sperm selection including MACS, used after sperm DNA fragmentation testing in male-factor infertility, has insufficient moderate- or high-quality evidence for improved chances of having a baby. That is a statement about the strength of the evidence, not a claim that MACS is harmful.

    Why a lower DFI reading is not a proven benefit

    A fall in measured DNA fragmentation after sorting is a real laboratory observation, but it sits several steps away from a live birth. Between the two lie fertilisation, embryo development, transfer and the many other factors that shape an IVF cycle. A surrogate marker can move in a helpful direction while the clinical endpoint stays unchanged — or the studies are simply too small and too varied to tell.

    This is why a clinic’s statement that MACS “reduces DNA fragmentation” should be read precisely. It may be accurate about the laboratory. It does not, on its own, establish that your chance of a baby improves.

    Limitations worth weighing

    When you read a study or a clinic’s summary, these are the questions that separate a strong claim from a weak one:

    • Sample size and design. Was it randomised, how many couples took part, and was it a single centre?
    • Protocol variation. MACS preparation steps and sperm-handling methods differ between laboratories, so results may not transfer.
    • DFI assay variation. The HFEA notes that sperm DNA fragmentation test methods and interpretations are not standardised. Without a universal cut-off, “high DFI” means different things in different studies.
    • Patient selection. Groups defined by high DFI, previous failed cycles or unexplained infertility are not interchangeable, and a result in one group does not automatically apply to another.
    • Endpoint choice. A study reporting motility or DFI has not tested live birth.
    • Comparators. MACS may be compared with standard density-gradient preparation in one study and with another selection method in another.

    None of these limitations proves MACS cannot help. They explain why the evidence is described as insufficient rather than settled.

    Where MACS sits among sperm-selection options

    MACS is one of several laboratory techniques for choosing sperm, alongside methods such as IMSI and PICSI. They differ in what they select on and in how much clinical evidence supports each. If you are weighing them, the useful comparison is not which sounds more advanced but what each is claimed to change, which outcomes have been studied, and whether the clinic can explain the evidence it relies on. A separate comparison of MACS versus IMSI sperm selection may help you frame that discussion.

    It also helps to keep the starting point clear. Sperm DNA fragmentation testing is itself an area where methods and interpretation vary, so a result should be discussed with a clinician who can put it in the context of your history. If testing is being considered at an older paternal age, the questions in this guide to sperm DNA fragmentation testing at older paternal age are a reasonable place to begin.

    Using this in a consultation

    You are entitled to ask a licensed clinician directly about diagnosis, options, risks, reports and your individual chances. A short, specific list tends to get clearer answers than a general request for an opinion.

    1. Does this clinic offer MACS, and in which situations is it proposed?
    2. What evidence does the clinic rely on, and does it distinguish laboratory findings from pregnancy or live-birth outcomes?
    3. Is MACS included in the written quotation, or is it an add-on with a separate charge? Ask for the inclusion to be stated in writing.
    4. How does MACS relate to other sperm-selection options the clinic offers, and what would change in the plan if it were not used?
    5. What does my own DFI result mean in my case, given the assay used and my history?

    If you are preparing for a first conversation, the broader questions in male factor infertility and PGT: questions to ask before you plan can sit alongside this list. For the practical side of sample preparation and paperwork, see the PGT IVF partner and sperm requirements checklist.

    What coordination can and cannot do

    Deciding whether MACS is appropriate is a clinical judgement for the treating team, based on your records and history. A coordination service works on a different layer: helping you organise goals and questions before you approach a hospital, keeping records and document requests in order, coordinating appointment and remote-consultation requests, assisting with travel and language needs around confirmed appointments, and helping with records handover and follow-up questions after you return home. It does not diagnose, prescribe or interpret results for you, and it cannot promise that a technique will be available or funded.

    A practical way to use that support is to ask for a written scope and inclusion comparison with unconfirmed fields clearly marked — for example, whether sperm selection is listed as included, optional or not offered. That document is something you can take into the consultation, rather than a substitute for it.

    The bottom line

    MACS has a coherent biological rationale and can change laboratory measures of sperm damage. What it does not yet have is consistent, high-quality evidence that it improves the chance of having a baby, which is why the HFEA describes the evidence as insufficient and why it is not established as routine. Treat claims that it “fixes” DNA fragmentation with caution, ask how laboratory findings relate to pregnancy outcomes, and let the treating clinician advise on your individual situation.

  • PGT-A vs PGT-SR: What Each Test Looks For and Why the Difference Matters

    PGT-A and PGT-SR are both preimplantation genetic tests performed on a small sample of cells taken from an embryo. The similarity ends there. PGT-A asks a broad question about chromosome number across the embryo’s chromosomes. PGT-SR asks a narrow, pre-defined question about chromosomes affected by a structural rearrangement already known to exist in a parent. One is a screening approach; the other is a targeted test built around a specific family finding.

    If a clinic has mentioned “PGT” without saying which one, the first useful step is to establish which test is actually being proposed and why. The two are not interchangeable, and PGT-SR is not a more thorough version of PGT-A.

    The core difference in one sentence each

    • PGT-A looks at chromosome number — aneuploidy — across the embryo’s chromosomes, to identify embryos with an abnormal number of whole chromosomes.
    • PGT-SR is designed for embryos from a parent who carries a known chromosomal structural rearrangement, such as a translocation or inversion, and looks for unbalanced chromosome content arising from that rearrangement.

    The UK regulator’s patient information describes PGT-A as assessing chromosome number in sampled embryo cells, and separately describes PGT-SR as addressing chromosomal structural rearrangements — different questions requiring different test design. That distinction is the heart of the matter.

    Why the indications differ

    PGT-A is typically raised in conversations about age-related risk, a history of recurrent pregnancy loss, or certain male-factor situations, where the concern is a random chromosome-number error in the embryo. PGT-SR enters the conversation through a different door: a karyotype result, or another genetic finding, showing that a parent carries a balanced structural rearrangement.

    A balanced rearrangement can leave a parent healthy while raising the chance that an embryo inherits an unbalanced amount of chromosome material. PGT-SR is built to look for that specific pattern. It is not a general screen for aneuploidy across all chromosomes, and it does not replace PGT-A unless the treating team has designed it to do both.

    Why PGT-SR needs preparation PGT-A does not

    PGT-SR cannot be ordered as a generic add-on. It depends on prior information:

    1. A documented parental karyotype or equivalent finding identifying the rearrangement and the chromosomes involved.
    2. A tailored probe design built around that specific rearrangement, which takes laboratory work before an embryo biopsy can be interpreted.
    3. Genetic counselling to explain inheritance patterns, what the test can and cannot detect, and what the results mean for the family.

    This is why the practical preparation for PGT-SR often starts months before a cycle, not at the clinic door. If you are travelling internationally, ask early whether your existing karyotype report is sufficient or whether the laboratory needs additional information or a repeat sample before probe design can begin.

    What a “normal” result means — and does not mean

    PGT-A PGT-SR
    What is examined Chromosome number across the embryo’s chromosomes Chromosome content related to the known parental rearrangement
    What “normal” suggests No aneuploidy detected in the sampled cells No unbalanced content from the rearrangement detected in the sampled cells
    What it cannot confirm That the whole embryo is normal, or that pregnancy will follow That the embryo is free of all chromosome issues, or that pregnancy will follow

    Both tests work from a biopsy sample, not the whole embryo. The regulator notes that PGT-A has limitations and can produce incorrect findings, and that a result does not guarantee a successful pregnancy or a healthy child. The same caution applies to PGT-SR: a reassuring result reduces one specific concern but does not certify the embryo.

    Mosaic findings add another layer. A mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample, and technical factors can contribute to such findings. A sampled result does not establish the cell composition of the whole embryo. Results and their uncertainty should be discussed with the treating clinician and a genetic counsellor.

    Practical preparation for international patients

    Before comparing quotes or booking travel, clarify these points in writing:

    • Which test is being quoted. Ask for the test name, the chromosomes it covers, and whether PGT-A and PGT-SR are being combined or offered separately.
    • Whether a parental karyotype is needed first. For PGT-SR, confirm whether your existing report is accepted and whether probe design must be completed before a cycle starts.
    • What records to gather. Karyotype reports, genetic counselling notes, previous PGT reports and any relevant family history should travel with you in dated copies.
    • Who explains the results. Confirm whether results are discussed by the treating clinician, a genetic counsellor, or both, and in what language.
    • What happens if the test is inconclusive. Ask how a failed or uninformative result would be handled and whether additional costs apply.

    Patients can and should ask licensed clinicians about diagnosis, test options, risks, reports and individual chances. A coordination service can help organise records, request appointments and compare what each quote includes, but it does not diagnose, interpret results or recommend a particular test.

    Where the two tests sit alongside PGT-M

    PGT-M addresses a known monogenic condition, PGT-SR addresses a known structural rearrangement, and PGT-A addresses chromosome number. Each answers a different question, and none is a universal requirement. Whether any of them is appropriate depends on your history, your records and a clinical assessment — not on a general claim that more testing is better.

    If you are weighing a previous IVF plan against a new proposal, it helps to compare the tests named in each plan side by side, including what each was meant to detect. A structured comparison of recommendations can make those differences visible before a consultation.

    Frequently asked questions

    Can PGT-SR also detect aneuploidy?

    PGT-SR is designed around a specific parental structural rearrangement and the chromosomes involved. Whether a clinic's PGT-SR protocol also reports general chromosome-number findings varies by laboratory and test design, so ask the treating team exactly what a given report will and will not cover rather than assuming.

    Do I need a karyotype before starting PGT-SR?

    PGT-SR depends on a documented parental rearrangement so that a tailored probe can be designed. Ask the laboratory whether your existing karyotype report is sufficient or whether additional information or a repeat sample is needed, and how long probe design takes before a cycle can begin.